Alentis Therapeutics Doses First ANCA-Associated Vasculitis

Alentis Therapeutics Doses First ANCA-Associated Vasculitis Rapidly Progressive Glomerulonephritis Patient in Phase 2 Clinical Trial of Lixudebart (ALE.F02)

Alentis Therapeutics Doses First ANCA-Associated Vasculitis Rapidly Progressive Glomerulonephritis Patient in Phase 2 Clinical Trial of Lixudebart (ALE.F02)

finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Related Keywords

France , Cambridge , Cambridgeshire , United Kingdom , Denmark , Switzerland , French , Stefan Klotter , Opatrick Wilson , Luigi Manenti , David Jayne , Thomas Baumert , Sariette Witte , Research Inserm , French National Institute Of Health , Aarhus University Hospital , Professor Of Clinical Autoimmunity At Cambridge University , University Of Strasbourg , Antineutrophil Cytoplasmic Antibody , Rapidly Progressive Glomerulonephritis , Chief Medical Officer , Clinical Professor , Principal Investigator , Clinical Autoimmunity , Cambridge University , Alentis Therapeutics , French National Institute , Medical Research , Public Relations Gmbh , Patrick Wilson , Lassen Sie ,